Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2007

01-08-2007 | Bone and Soft Tissue Sarcomas

Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis

Authors: Sherry J. Lim, Janice N. Cormier, Barry W. Feig, Paul F. Mansfield, Robert S. Benjamin, Janet R. Griffin, Judy L. Chase, Peter W. T. Pisters, Raphael E. Pollock, Kelly K. Hunt

Published in: Annals of Surgical Oncology | Issue 8/2007

Login to get access

Abstract

Background

Treatment of peritoneal recurrence following surgical resection of intra-abdominal sarcomas presents a significant challenge to clinicians. Historically, treatment with systemic chemotherapy has been ineffective and surgical resection alone has not been durable. We prospectively evaluated the feasibility of cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin (CDDP) alone or in combination with mitoxantrone (MITOX) for the treatment of sarcomatosis.

Methods

Two phase I trials of HIPEC were conducted (1998–2003). Eligible patients with evidence of sarcomatosis underwent cytoreductive surgery followed by HIPEC. In the first trial, CDDP dosing was established as 90 mg/m2 with a perfusate time of 90 minutes and temperature of 41°C. In the second trial, MITOX (20 mg/m2) was instilled following perfusion with CDDP. Toxicity, efficacy, and quality of life (QOL) were evaluated.

Results

A total of 28 patients were enrolled in the two trials. We noted a higher overall toxicity score and complication rate with combination CDDP/MITOX versus CDDP alone and shorter overall survival duration (5.5 months vs 16.9 months, respectively). In addition, local recurrence rates were similar in both groups (CDDP 79% vs CDDP/MITOX 68%). As expected, QOL scores at 6–8 weeks following HIPEC were 15–25% lower than the baseline scores; however, they returned to baseline at 3–6 months.

Conclusions

Although the HIPEC technique is feasible for patients with sarcomatosis, it is associated with significant toxicity and limited clinical benefit. Combination CDDP/MITOX failed to demonstrate any benefit over CDDP alone; moreover, there was an increase in toxicity.
Literature
1.
Ross JA, Severson RK, Davis S, Brooks JJ. Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987. Cancer 1993;72(2):486–90PubMedCrossRef
2.
Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases. Int J Cancer 2006;119(12):2922–30PubMedCrossRef
3.
Cancer Facts and Figures 2006. American Cancer Society 2006
4.
Ferrario T, Karakousis CP. Retroperitoneal sarcomas: grade and survival. Arch Surg 2003; 138(3):248–51PubMedCrossRef
5.
Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995; 221(4):392–7PubMedCrossRef
6.
Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215(1):68–77PubMedCrossRef
7.
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350(9092):1647–54CrossRef
8.
Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg 1990; 212(1):51–9PubMedCrossRef
9.
Mendenhall WM, Zlotecki RA, Hochwald SN, et al. Retroperitoneal soft tissue sarcoma. Cancer 2005; 104(4):669–75PubMedCrossRef
10.
Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer 2002; 94(9):2441–6PubMedCrossRef
11.
Farma JM, Pingpank JF, Libutti SK, et al. Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg 2005; 9(9):1346–53PubMedCrossRef
12.
Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240(2):278–85PubMedCrossRef
13.
Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243(2):212–2PubMedCrossRef
14.
Kikuchi K, Yamagata S, Yoshizumi M, Watanabe R. [Evaluation of intraperitoneal perfusion of COPP in peritonitis carcinomatosis]. Gan No Rinsho 1965; 11(12):834–7PubMed
15.
Vernick JJ, Oates GD, Magell J, Fried C. The use of anticancer agents for control of tumor growth in the peritoneal cavity after seeding with an experimental tumor. J Surg Res 1964; 4:559–61PubMed
16.
Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40(2):256–60PubMed
17.
Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106(9):1933–9PubMedCrossRef
18.
Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11(4):393–8PubMedCrossRef
19.
Mahteme H, Sugarbaker PH. Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin. Br J Surg 2004; 91(9):1168–73PubMedCrossRef
20.
Stewart JHt, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006; 13(5):624–4PubMedCrossRef
21.
Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27(3):239–43PubMedCrossRef
22.
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1):34–43PubMedCrossRef
23.
Abu-Surrah AS, Kettunen M. Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Curr Med Chem 2006; 13(11):1337–57PubMedCrossRef
24.
Kokufu I, Kurokawa E, Akashi H, et al. [Hepatic metastases from jejunal leiomyosarcoma treated effectively by repeated transarterial embolization with carboplatin]. Gan To Kagaku Ryoho 1993; 20(1):141–3PubMed
25.
Mavligit GM, Zukiwski AA, Salem PA, et al. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer 1991; 68(2):321–3PubMedCrossRef
26.
Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13(2):229–37PubMedCrossRef
27.
Muller H, Nakchbandi V. Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)—report of six cases. Eur J Surg Oncol 2004; 30(5):573–7PubMedCrossRef
28.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22(16):3284–92PubMedCrossRef
29.
Dietel M, Arps H, Gerding D, et al. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin. J Cancer Res Clin Oncol 1988; 114(2):197–203PubMedCrossRef
30.
Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 1983; 10(2):103–15PubMedCrossRef
31.
Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 1990; 18(5):365–80PubMed
32.
Schopman EM, Van Bree C, Bakker PJ, et al. Hyperthermia-enhanced effectiveness of mitoxantrone in an experimental rat tumour. Int J Hyperthermia 1996; 12(2):241–54PubMed
33.
Wiedemann G, Mella O, Roszinski S, et al. Hyperthermia enhances mitoxantrone cytotoxicity on human breast carcinoma and sarcoma xenografts in nude mice. Int J Radiat Oncol Biol Phys 1992; 24(4):669–73PubMed
34.
Eilber FC, Rosen G, Forscher C, et al. Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000; 9(2):71–5PubMedCrossRef
35.
Eilber FC, Rosen G, Forscher C, et al. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999; 6(7):645–50PubMedCrossRef
36.
Common Toxicity Criteria. Washington D.C.: National Cancer Institute, 1999
37.
Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF−36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473–83PubMedCrossRef
38.
Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11(3):570–9PubMed
39.
Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999; 35(3):413–9PubMedCrossRef
40.
Bonvalot S, Cavalcanti A, Le Pechoux C, et al. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur J Surg Oncol 2005; 31(8):917–23PubMedCrossRef
41.
Rossi CR, Deraco M, De Simone M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer 2004; 100(9):1943–50PubMedCrossRef
42.
Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002; 94(2):492–9PubMedCrossRef
43.
Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002; 13(2):267–72PubMedCrossRef
44.
Rossi CR, Mocellin S, Pilati P, et al. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am 2003; 12(3):781–94PubMedCrossRef
45.
Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002; 13(3):181–209PubMedCrossRef
46.
Rufian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006; 94(4):316–24PubMedCrossRef
47.
Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10(8):863–9PubMedCrossRef
48.
Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004; 139(1):20–26PubMedCrossRef
49.
Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138(1):26–33PubMedCrossRef
50.
Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14(3):254–61PubMedCrossRef
51.
van der Vange N, van Goethem AR, Zoetmulder FA, et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000; 26(7):663–8PubMedCrossRef
52.
McQuellon RP, Loggie BW, Fleming RA, et al. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27(1):65–73PubMedCrossRef
53.
McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10(2):155–62PubMedCrossRef
54.
Mudan SS, Conlon KC, Woodruff JM, et al. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000; 88(1):66–74PubMedCrossRef
Metadata
Title
Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis
Authors
Sherry J. Lim
Janice N. Cormier
Barry W. Feig
Paul F. Mansfield
Robert S. Benjamin
Janet R. Griffin
Judy L. Chase
Peter W. T. Pisters
Raphael E. Pollock
Kelly K. Hunt
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9463-z

Other articles of this Issue 8/2007

Annals of Surgical Oncology 8/2007 Go to the issue

OriginalPaper

Prognostic Factors in Primary Gastric Lymphoma

Breast Oncology

Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases after a Positive Sentinel Node Biopsy

Breast Oncology

Superiority of Sonographic Hematoma Guided Resection of Mammogram Only Visible Breast Cancer: Wire Localization Should be an Exception—Not the Rule

Editorial

SEER Data: It Can Be Thought Provoking, But Where Do We Go From Here?

Laboratory Research

Use of an Artificial Lymphatic System During Carboplatin Infusion to Improve Canine Osteosarcoma Blood Flow and Clinical Response

Breast

Validation and Limitations of Use of a Breast Cancer Nomogram Predicting the Likelihood of Non–Sentinel Node Involvement After Positive Sentinel Node Biopsy